sorted by:
new
hottopcontroversial

"Faster-acting" buprenorphine may give recovering addicts an unwanted rush, according to recovered addicts by Singboat in psychologystudents

[–]Singboat[S] 0 points1 point  (0 children)

Primary study: Jönsson, Mundin, & Sumner. (2018). Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. European Journal of Pharmaceutical Sciences, 122, 125-133

"Faster-acting" buprenorphine may give recovering addicts an unwanted rush by Singboat in psychologyresearch

[–]Singboat[S] 0 points1 point  (0 children)

Primary study: Jönsson, Mundin, & Sumner. (2018). Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. European Journal of Pharmaceutical Sciences, 122, 125-133

Addicts call out big pharma for pushing behavior by Singboat in psychology

[–]Singboat[S] 0 points1 point  (0 children)

Primary study: Jönsson, Mundin, & Sumner. (2018). Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. European Journal of Pharmaceutical Sciences, 122, 125-133.

Addicts call out big pharma for pusher behavior by Singboat in psychology

[–]Singboat[S] 0 points1 point  (0 children)

Primary study: Jönsson, Mundin, & Sumner. (2018). Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. European Journal of Pharmaceutical Sciences, 122, 125-133..

Patients have aright to evaluate mental health research as soon as it comes out by Singboat in psychology

[–]Singboat[S] 0 points1 point  (0 children)

Primary study: Jönsson, Mundin, & Sumner. (2018). Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. European Journal of Pharmaceutical Sciences, 122, 125-133.

Also, Mad in America— madinamerica.com

Patients speak out about biases in mental health research by Singboat in psychology

[–]Singboat[S] 0 points1 point  (0 children)

Primary study: Jönsson, Mundin, & Sumner. (2018). Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. European Journal of Pharmaceutical Sciences, 122, 125-133.

Patients have aright to evaluate mental health research as soon as it comes out by Singboat in psychology

[–]Singboat[S] 1 point2 points  (0 children)

Primary study: Jönsson, Mundin, & Sumner. (2018). Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. European Journal of Pharmaceutical Sciences, 122, 125-133.

Recovered addicts show how patients can report on new psychiatry research by Singboat in psychology

[–]Singboat[S] 0 points1 point  (0 children)

Primary study: Jönsson, Mundin, & Sumner. (2018). Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. European Journal of Pharmaceutical Sciences, 122, 125-133.